Processing

Please wait...

Settings

Settings

1. NZ602754 - Substituted 1,3-benzothiazepines useful in treating metabolic disorders

Office New Zealand
Application Number 602754
Application Date 27.04.2011
Publication Number 602754
Publication Date 30.05.2014
Grant Number
Grant Date 02.09.2014
Publication Kind B
IPC
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
55
having seven-membered rings, e.g. azelastine, pentylenetetrazole
554
having at least one nitrogen and at least one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3
Drugs for disorders of the metabolism
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
5
Drugs for disorders of the endocrine system
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
281
Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
02
Seven-membered rings
04
having the hetero atoms in positions 1 and 4
08
condensed with carbocyclic rings or ring systems
10
condensed with one six-membered ring
A61K 31/554
A61P 3/00
A61P 5/00
C07D 281/10
CPC
C07D 281/10
C07D 417/06
C07F 9/6541
A61K 31/554
A61K 31/675
C07D 285/36
Applicants GLAXOSMITHKLINE LLC
Inventors AQUINO, Christopher Joseph
COLLINS, Jon Loren
COWAN, David John
WU, Yulin
Agents HENRY HUGHES IP LIMITED
Priority Data 61/328,212 27.04.2010 US
61/329,225 29.04.2010 US
Title
(EN) Substituted 1,3-benzothiazepines useful in treating metabolic disorders
Abstract
(EN)
602754 Provided are dioxido-phenyl-benzothiazepin derivatives of formula (I), where Q, R1, R2, R3, R4 and X are as defined in the specification. An example of the derivatives is 3-({[(3R,5R)-3-butyl-3-ethyl-7-(methyloxy)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,4-benzothiazepin-8-yl]carbonyl}amino)-2,2-dimethylpropanoic acid. Methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and therapeutic uses of them are further provided. These compounds are suitable for treating metabolic disorders, particularly diabetes mellitus (Type I and Type II) or obesity.